We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

35 hedge funds and large institutions have $24.7M invested in Xilio Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

96% more capital invested

Capital invested by funds: $12.6M → $24.7M (+$12.1M)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

6% more funds holding

Funds holding: 33 → 35 (+2)

1.45% more ownership

Funds ownership: 2.59% → 4.04% (+1.4%)

Holders
35
Holders Change
+2
Holders Change %
+6.06%
% of All Funds
0.46%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.07%
New
9
Increased
6
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UBS Group
UBS Group
Switzerland
+$230K
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$69.5K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$48.2K
4
ACA
Aptus Capital Advisors
Alabama
+$40.3K
5
Citadel Advisors
Citadel Advisors
Florida
+$39.6K

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$512K
2
TSS
Two Sigma Securities
New York
-$35K
3
EGM
Engineers Gate Manager
New York
-$25.8K
4
Millennium Management
Millennium Management
New York
-$16.3K
5
APP
Avantax Planning Partners
Iowa
-$16.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
GS
1
Gilead Sciences
California
$8.7M +$8.95M +650,389 New
BCLSI
2
Bain Capital Life Sciences Investors
Massachusetts
$4.36M – – –
RSCM
3
Rock Springs Capital Management
Maryland
$2.87M – – –
MC
4
Merck & Co
New Jersey
$1.42M +$1.46M +105,983 New
TPC
5
Takeda Pharmaceutical Company
Japan
$1.42M – – –
Fidelity Investments
6
Fidelity Investments
Massachusetts
$1.33M – – –
Morgan Stanley
7
Morgan Stanley
New York
$956K -$512K -37,196 -34%
Vanguard Group
8
Vanguard Group
Pennsylvania
$862K – – –
AIIC
9
AJU IB Investment Company
South Korea
$638K +$656K +47,696 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$342K +$19.9K +1,445 +6%
Balyasny Asset Management
11
Balyasny Asset Management
Illinois
$328K +$69.5K +5,053 +26%
Renaissance Technologies
12
Renaissance Technologies
New York
$283K +$29.8K +2,166 +11%
TOCUITCONY
13
Trustees of Columbia University in the City of New York
New York
$238K +$245K +17,831 New
UBS Group
14
UBS Group
Switzerland
$238K +$230K +16,690 +1,485%
Fidelity International
15
Fidelity International
Bermuda
$209K – – –
BlackRock
16
BlackRock
New York
$72.7K +$454 +33 +0.6%
BCM
17
Bridgeway Capital Management
Texas
$67.9K – – –
Raymond James Financial
18
Raymond James Financial
Florida
$47.8K +$49.2K +3,578 New
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$46.9K +$48.2K +3,507 New
State Street
20
State Street
Massachusetts
$41.4K – – –
ACA
21
Aptus Capital Advisors
Alabama
$39.2K +$40.3K +2,929 New
Citadel Advisors
22
Citadel Advisors
Florida
$38.5K +$39.6K +2,880 New
Northern Trust
23
Northern Trust
Illinois
$37.4K – – –
SFG
24
SevenBridge Financial Group
Pennsylvania
$26.9K – – –
Mariner
25
Mariner
Kansas
$23.9K -$303 -22 -1%
1
2

XLO Hedge Fund Activity: Q4 2024 in Review

35 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q4 2024, worth a combined $24.7M — up 96% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new XLO positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was UBS Group, adding an estimated $230K. The largest seller was Morgan Stanley, cutting an estimated $512K.

  • 35 institutional investors held Xilio Therapeutics (XLO) as of Q4 2024, up from 33 in Q3 2024.
  • Funds reported $24.7M of Xilio Therapeutics stock for Q4 2024, up 96% quarter-over-quarter.
  • 9 funds opened new Xilio Therapeutics positions in Q4 2024 and 5 closed out, a net change of +4 holders.
  • The largest Xilio Therapeutics buyer in Q4 2024 was UBS Group, an estimated $230K added.
  • The largest Xilio Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $512K sold.

Based on aggregated 13F filings for Q4 2024.